Translational Neurophysiology for CNS Development
EEG Analytics for Translational Medicine and Clinical Development
Neuromap™ supports pharmaceutical and biotechnology teams investigating brain function, target-engagement hypotheses, exposure-related change and exploratory neurophysiology across healthy-volunteer and participant studies.
Where Neuromap™ can add value
Early-phase and healthy-volunteer studies
Support repeatable baseline, pre-dose, post-dose, dose-escalation, crossover and time-course EEG analysis.
Translational medicine
Link preclinical or mechanistic hypotheses to prospectively defined human EEG-derived variables where the design supports translation.
Exploratory pharmacodynamics
Evaluate whether exposure is associated with predefined neurophysiological change without overstating causality or clinical relevance.
Candidate biomarker programmes
Generate, prioritise and document exploratory variables for later independent validation.
Neurodegeneration and movement disorders
Support longitudinal and intervention-related research across Parkinson’s, cognitive ageing and other protocol-defined CNS programmes.
Psychiatry and cognition
Examine arousal, spectral, network, complexity, vigilance and cognitive-performance variables.
Retrospective asset analysis
Assess existing EEG datasets for recoverable questions, harmonisation, subgroup hypotheses and future-study design.
Digital biomarker and neurotechnology collaboration
Provide an advanced EEG analytical layer for digital therapeutics, wearables, devices and combined-modality research.
Longitudinal and follow-up analysis
Track within-participant and cohort-level change across baseline, dosing, follow-up and extension visits using controlled, version-managed processing.
Questions the analytical plan can address
- Are baseline EEG-derived variables stable enough for the proposed design?
- Is there a measurable within-participant change after exposure?
- Does change follow dose, time, intervention phase or target-engagement expectations?
- Are effects global, regional, network-specific or state-dependent?
- Do candidate EEG changes correspond with cognitive, motor, behavioural, clinical or pharmacokinetic outcomes?
- Are there identifiable responder, non-responder or phenotype subgroups that warrant validation?
- Which acquisition or analysis limitations should change the next protocol?
Candidate biomarkers, not unsupported claims
Neuromap™ can evaluate EEG-derived candidate biomarkers and exploratory features, but the website does not represent those variables as validated diagnostic markers, surrogate endpoints or qualified regulatory biomarkers. Stronger claims require prespecified evidence, analytical validation, clinical validation, independent replication and the appropriate regulatory strategy.
Research Enhancement and intervention-evaluation support
For non-pharmacological, combination or enhancement-oriented research, Neuromap™ can define baseline variables, compare intervention phases, identify preserved and changing domains, integrate functional outcomes and produce research guidance for protocol refinement. This is particularly relevant to digital therapeutics, cognitive training, rehabilitation, sleep, exercise, nutrition and neuromodulation studies.
From pilot to scaled programme
- Scientific and technical feasibility review.
- Representative sample-file assessment.
- Prospective analysis specification and quality plan.
- Pilot processing with agreed acceptance criteria.
- Locked production configuration and controlled delivery.
- Milestone review, longitudinal analysis and study-level reporting.
- Methods, data dictionary and publication support.
Designed to complement the development team
Neuromap™ complements, rather than replaces, sponsor medical monitoring, clinical EEG safety review, clinical pharmacology, biostatistics, regulatory strategy, data management and investigator responsibilities. Interfaces, decision rights and escalation pathways are agreed before study start.
Data and governance expectations
Study data are handled through a documented transfer and access model. The sponsor and Neuromap™ define controller and processor roles, permitted data, pseudonymisation, security, retention, audit, sub-processing and international-transfer requirements. For UK CTIMPs, delegated work is documented within the sponsor’s GCP oversight and quality framework.
Frequently asked questions
Common questions about EEG analytics for drug development.
Can Neuromap™ support a first-in-human study?
Potentially. Feasibility depends on the scientific question, acquisition schedule, equipment, variables, turnaround and governance requirements.
Can EEG outputs be linked with PK or clinical data?
Yes, where authorised identifiers, time alignment, data standards and the analysis plan support integration.
Can Neuromap™ identify responders?
Exploratory responder analysis can be performed using prespecified or clearly labelled post hoc criteria. Findings require validation and must not be presented as established predictive biomarkers without evidence.
Can you support publication after study close?
Yes. Neuromap™ can support EEG methods, data dictionaries, figures, tables and scientific interpretation under an agreed publication plan.